TY - JOUR
T1 - Glucocorticoid-induced ocular hypertension
T2 - origins and new approaches to minimize
AU - Yorio, Thomas
AU - Patel, Gaurang C.
AU - Clark, Abbot F.
N1 - Funding Information:
Manuscript has been funded in part by the National Institutes of Health (grant 2 R01 EY016242).
Funding Information:
Thomas Yorio and Abbott F. Clark have received previous funding from the National Institutes of Health (NIH) for this study. Guarang C. Patel is also an employee of Regeneron. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Publisher Copyright:
© 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2020/5/3
Y1 - 2020/5/3
N2 - Introduction: Glucocorticoids (GCs) have unique actions in their combined anti-inflammatory and immunosuppressive activities and are among the most commonly prescribed drugs, particularly for inflammatory conditions. They are often used clinically to treat inflammatory eye diseases like uveitis, optic neuritis, conjunctivitis, keratitis, and others, but are often accompanied by side effects, like ocular hypertension that can be vision threatening. Areas covered: The review will focus on the complex molecular mechanism of action of GCs that involve both transactivation and transrepression and their use therapeutically that can cause significant systemic side effects, particularly ocular hypertension that can lead to glaucoma. Expert Opinion: While we are still unclear as to all the mechanisms responsible for GC-induced ocular hypertension, however, there are potential novel therapies that are in development that can separate some of the anti-inflammatory therapeutic efficacy from their ocular hypertension side effect. This review provides some insight into these approaches.
AB - Introduction: Glucocorticoids (GCs) have unique actions in their combined anti-inflammatory and immunosuppressive activities and are among the most commonly prescribed drugs, particularly for inflammatory conditions. They are often used clinically to treat inflammatory eye diseases like uveitis, optic neuritis, conjunctivitis, keratitis, and others, but are often accompanied by side effects, like ocular hypertension that can be vision threatening. Areas covered: The review will focus on the complex molecular mechanism of action of GCs that involve both transactivation and transrepression and their use therapeutically that can cause significant systemic side effects, particularly ocular hypertension that can lead to glaucoma. Expert Opinion: While we are still unclear as to all the mechanisms responsible for GC-induced ocular hypertension, however, there are potential novel therapies that are in development that can separate some of the anti-inflammatory therapeutic efficacy from their ocular hypertension side effect. This review provides some insight into these approaches.
KW - Glucocorticoids
KW - SEGRAs
KW - glaucoma
KW - glucocorticoid molecular mechanisms
KW - ocular hypertension
UR - http://www.scopus.com/inward/record.url?scp=85085491173&partnerID=8YFLogxK
U2 - 10.1080/17469899.2020.1762488
DO - 10.1080/17469899.2020.1762488
M3 - Review article
AN - SCOPUS:85085491173
SN - 1746-9899
VL - 15
SP - 145
EP - 157
JO - Expert Review of Ophthalmology
JF - Expert Review of Ophthalmology
IS - 3
ER -